Zydus receives USFDA Orphan Drug Designation for Usnoflast to treat ALS

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for treating amyotrophic lateral sclerosis (ALS), a rare fatal neurodegenerative disease. Clinical trials indicate promising results, and further trials are planned. ALS affects over 30,000 people in the US annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X4j6eJk
via IFTTT